Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
183.69
+7.33 (4.16%)
Aug 20, 2026, 1:38 PM EDT - Market open
Repligen Revenue
Repligen had revenue of $204.13M in the quarter ending June 30, 2026, with 11.93% growth. This brings the company's revenue in the last twelve months to $785.10M, up 16.49% year-over-year. In the year 2025, Repligen had annual revenue of $738.26M with 16.36% growth.
Revenue (ttm)
$785.10M
Revenue Growth
+16.49%
P/S Ratio
13.16
Revenue / Employee
$392,551
Employees
2,000
Market Cap
10.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 738.26M | 103.82M | 16.36% |
| Dec 31, 2024 | 634.44M | 2.08M | 0.33% |
| Dec 31, 2023 | 632.36M | -169.17M | -21.11% |
| Dec 31, 2022 | 801.54M | 131.00M | 19.54% |
| Dec 31, 2021 | 670.53M | 304.27M | 83.08% |
| Dec 31, 2020 | 366.26M | 96.02M | 35.53% |
| Dec 31, 2019 | 270.25M | 76.21M | 39.28% |
| Dec 31, 2018 | 194.03M | 52.80M | 37.38% |
| Dec 31, 2017 | 141.24M | 36.70M | 35.10% |
| Dec 31, 2016 | 104.54M | 21.00M | 25.14% |
| Dec 31, 2015 | 83.54M | 19.99M | 31.45% |
| Dec 31, 2014 | 63.55M | -4.62M | -6.78% |
| Dec 31, 2013 | 68.17M | 5.90M | 9.48% |
| Dec 31, 2012 | 62.27M | 34.98M | 128.16% |
| Mar 31, 2011 | 27.29M | 6.32M | 30.14% |
| Mar 31, 2010 | 20.97M | -8.39M | -28.58% |
| Mar 31, 2009 | 29.36M | 10.07M | 52.16% |
| Mar 31, 2008 | 19.30M | 5.22M | 37.10% |
| Mar 31, 2007 | 14.07M | 1.16M | 9.01% |
| Mar 31, 2006 | 12.91M | 3.55M | 37.94% |
| Mar 31, 2005 | 9.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Baxter International | 11.47B |
| Solventum | 8.31B |
| Avantor | 6.56B |
| Bausch + Lomb | 5.32B |
| The Cooper Companies | 4.23B |
| Align Technology | 4.14B |
| AptarGroup | 3.93B |
| MiniMed Group | 3.10B |
RGEN News
- 1 day ago - Stifel sees Moderna data as positive for Repligen, Maravai - TheFly
- 1 day ago - Wells sees Repligen among key beneficiaries of Moderna’s cancer vaccine data - TheFly
- 22 days ago - Repligen Stock (RGEN) Rises After Investors Wowed By ‘Market Leading’ Q2 Figures - TipRanks
- 22 days ago - Repligen price target raised to $175 from $165 at JPMorgan - TheFly
- 23 days ago - Repligen rises 15.4% - TheFly
- 23 days ago - Repligen rises 16.2% - TheFly
- 23 days ago - Repligen Earnings Call Transcript: Q2 2026 - Transcripts
- 23 days ago - Repligen Earnings release: Q2 2026 - Filings